Holen Sie sich die Stockscreener-App
0.0002
60.00%
-0.0003
Syros Pharmaceuticals Inc Aktie (SYRS) Neueste Nachrichten
MSN - MSN
MSN Money - MSN
Myelodysplastic Syndrome Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Globe and Mail
Reviewing Vectura Group (OTCMKTS:VEGPF) and Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Head-To-Head Review: Aerovate Therapeutics (NASDAQ:AVTE) vs. Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Syros to delist from Nasdaq, deregister from SEC - MSN
SYRS (Syros Pharmaceuticals) Price-to-Tangible-Book : (As of Oct. 22, 2025) - GuruFocus
CapEx per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Net current asset value per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN
AKPKD Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeut - The Globe and Mail
Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, - Barchart.com
Syros Pharmaceuticals, Inc. (SYRS) stock price, news, quote and history - Yahoo Finance Singapore
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - GlobeNewswire
Syros Pharmaceuticals (SYRS) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
SYRS Stock Price, News & Analysis - stocktitan.net
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), State Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN
Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com
Odyssey hires Jason Haas as CFO - BioCentury
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President - Business Wire
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com Australia
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - Nasdaq
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance
No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld MedTech
Syros stock dives 92% on failed Phase 3 study, possible loan default (NASDAQ:SYRS) - Seeking Alpha
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - Business Wire
CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight - The Malaysian Reserve
Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - simplywall.st
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gew - GuruFocus
Syros Pharmaceuticals, Inc. (SYRS) Investigation: - GlobeNewswire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings - Business Wire
How to contact the Daily Bulletin - FinancialContent
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - PR Newswire
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination - Nasdaq
Syros’ stock craters after Phase II AML trial termination due to inefficacy - Clinical Trials Arena
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial - Stock Titan
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update - Stock Titan
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why - Nasdaq
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout - Seeking Alpha
TD Cowen maintains Buy on Syros Pharmaceuticals stock amid trial optimism - Investing.com Canada
Irving’s McKesson Corp. Adds Healthcare Veteran to Board - Dallas Innovates
McKesson Elects Deborah Dunsire as Director - citybiz
Top 3 Health Care Stocks You'll Regret Missing This Month - Sahm
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire
Syros Pharmaceuticals (SYRS) Stock Forecast and Price Target 2025 - MarketBeat
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals - Yahoo Finance
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression - Business Wire
Syros Pharmaceuticals CMO sells over $50k in company stock By Investing.com - Investing.com Canada
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Earnings call: Syros Pharmaceuticals strong Q4 and full year financials - Investing.com
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why - Nasdaq
Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals - Yahoo Finance
Here’s What Insiders Are Buying to Wrap Up the Year - 24/7 Wall St.
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants - Business Wire
Syros stock jumps after data for leukemia drug (NASDAQ:SYRS) - Seeking Alpha
Syros Pharmaceuticals Inc (SYRS) Stock News & Articles - 24/7 Wall St.
2.90%
2.73%
Kapitalisierung:
|
Volumen (24h):